216 related articles for article (PubMed ID: 31680043)
1. CFTR processing, trafficking and interactions.
Amaral MD; Hutt DM; Tomati V; Botelho HM; Pedemonte N
J Cyst Fibros; 2020 Mar; 19 Suppl 1():S33-S36. PubMed ID: 31680043
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic approaches to CFTR dysfunction: From discovery to drug development.
Li H; Pesce E; Sheppard DN; Singh AK; Pedemonte N
J Cyst Fibros; 2018 Mar; 17(2S):S14-S21. PubMed ID: 28916430
[TBL] [Abstract][Full Text] [Related]
3. Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.
Hanrahan JW; Sato Y; Carlile GW; Jansen G; Young JC; Thomas DY
Expert Opin Ther Targets; 2019 Aug; 23(8):711-724. PubMed ID: 31169041
[No Abstract] [Full Text] [Related]
4. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
Amico G; Brandas C; Moran O; Baroni D
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
[TBL] [Abstract][Full Text] [Related]
5. Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR.
Bose SJ; Krainer G; Ng DRS; Schenkel M; Shishido H; Yoon JS; Haggie PM; Schlierf M; Sheppard DN; Skach WR
J Cyst Fibros; 2020 Mar; 19 Suppl 1(Suppl 1):S25-S32. PubMed ID: 31902693
[TBL] [Abstract][Full Text] [Related]
6. Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability.
Ferrera L; Baroni D; Moran O
J Cyst Fibros; 2019 Sep; 18(5):602-605. PubMed ID: 30738802
[TBL] [Abstract][Full Text] [Related]
7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
8. Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics.
Kim M; McDonald EF; Sabusap CMP; Timalsina B; Joshi D; Hong JS; Rab A; Sorscher EJ; Plate L
J Biol Chem; 2023 Oct; 299(10):105242. PubMed ID: 37690692
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
10. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
Bongiorno R; Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
[TBL] [Abstract][Full Text] [Related]
11. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological rescue of the mutant cystic fibrosis transmembrane conductance regulator (CFTR) detected by use of a novel fluorescence platform.
Holleran JP; Glover ML; Peters KW; Bertrand CA; Watkins SC; Jarvik JW; Frizzell RA
Mol Med; 2012 May; 18(1):685-96. PubMed ID: 22396015
[TBL] [Abstract][Full Text] [Related]
13. Repairing the basic defect in cystic fibrosis - one approach is not enough.
Farinha CM; Matos P
FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
[TBL] [Abstract][Full Text] [Related]
14. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
15. HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR.
Moniz S; Sousa M; Moraes BJ; Mendes AI; Palma M; Barreto C; Fragata JI; Amaral MD; Matos P
ACS Chem Biol; 2013 Feb; 8(2):432-42. PubMed ID: 23148778
[TBL] [Abstract][Full Text] [Related]
16. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
Cai ZW; Liu J; Li HY; Sheppard DN
Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
[TBL] [Abstract][Full Text] [Related]
17. Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.
Brusa I; Sondo E; Falchi F; Pedemonte N; Roberti M; Cavalli A
J Med Chem; 2022 Apr; 65(7):5212-5243. PubMed ID: 35377645
[TBL] [Abstract][Full Text] [Related]
18. miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells.
Kumar P; Bhattacharyya S; Peters KW; Glover ML; Sen A; Cox RT; Kundu S; Caohuy H; Frizzell RA; Pollard HB; Biswas R
Gene Ther; 2015 Nov; 22(11):908-16. PubMed ID: 26133785
[TBL] [Abstract][Full Text] [Related]
19. Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.
Birault V; Solari R; Hanrahan J; Thomas DY
Curr Opin Chem Biol; 2013 Jun; 17(3):353-60. PubMed ID: 23711435
[TBL] [Abstract][Full Text] [Related]
20. An overview on chemical structures as ΔF508-CFTR correctors.
Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
